Achieved ~25% worldwide revenue growth and positive adjusted EBITDA First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Recent Operational Highlights (any comparisons are to the prior year period) SANTA CLARA, Calif. May 5, 2025 - SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended March 31, 2025. "Our momentum continues unabated with a strong start to 2025, as we outperfo ...

Core Insights - SI-BONE, Inc. reported strong financial results for Q1 2025, with significant revenue growth and improved profitability metrics [3][4][7]. Financial Performance - Worldwide revenue reached $47.3 million, a 24.9% increase from $37.9 million in Q1 2024 [4][9]. - U.S. revenue was $44.8 million, reflecting a 26.6% increase from $35.4 million in the same period last year [4][9]. - Gross profit was $37.7 million, up 26.2% from $29.9 million in Q1 2024, with a gross margin of 79.7%, an improvement of 80 basis points [5][9]. - Operating expenses increased by 7.8% to $45.2 million, driven by higher commercial activity and R&D investments [6][9]. - Operating loss improved by 37.9% to $7.5 million, while net loss decreased by 40.0% to $6.5 million, or $0.15 per diluted share [7][9]. - Adjusted EBITDA was positive at $0.5 million, a significant improvement from an adjusted EBITDA loss of $4.0 million in Q1 2024 [8][9]. Operational Highlights - The company added over 300 active U.S. physicians in the quarter, totaling over 1,400, representing a 27.3% growth [9]. - The strong underlying procedure demand and the rollout of new products contributed to revenue growth [4][9]. Guidance and Outlook - SI-BONE updated its 2025 revenue guidance to a range of $193.5 million to $197.5 million, implying year-over-year growth of approximately 16% to 18% [10][11]. - The company expects a gross margin of 78% for the full year and anticipates operating expenses to grow at around 10% [10][11].

Core Insights - SI-BONE, Inc. will report its financial results for Q1 2025 on May 5, 2025, after market close, with a conference call scheduled for 1:30 p.m. Pacific Time [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,300 physicians and performed over 115,000 procedures since 2009 [3] Company Overview - SI-BONE has pioneered minimally invasive SI joint surgery and has a strong clinical evidence base, including two randomized controlled trials and over 160 peer-reviewed publications [3] - The company has expanded its offerings to adjacent markets, including adult deformity, sacropelvic fixation, and pelvic trauma [3] Investor Information - Investors can listen to the conference call by registering online, and a live audio webcast will be available on the company's website [2] - The webcast will be archived for at least 90 days for replay [2]

2 Market Leader in the Sacropelvic Space SI-BONE Corporate Overview February 2025 Safe Harbor Statement This presentation contains "forward-looking statements," which are statements related to events, results, activities or developments that SI-BONE expects, believes or anticipates will or may occur in the future. Forward-looking often contain words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and simi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (408) 207-0700 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38701 SI-BONE, Inc. (Exact name of Registrant as specified in its ...

Financial Data and Key Metrics Changes - The company reported a record $49 million in worldwide revenue for Q4 2024, representing growth exceeding 26% compared to the previous year [9][41] - U.S. revenue increased by 28% to $46.9 million, driven by strong demand from nearly 1,400 active physicians [10][41] - Gross profit for Q4 increased by 35% to $38.8 million, with a gross margin of 79% [43] - The net loss improved by nearly 60% to $4.5 million, or $0.11 per diluted share [45] - Positive adjusted EBITDA of $1.9 million was achieved in Q4, compared to an adjusted EBITDA loss of $4.8 million in Q4 2023 [46] Business Line Data and Key Metrics Changes - The SI joint fusion procedures saw a surge in demand, particularly with the adoption of the TORQ and INTRA products [11][24] - The Granite 9.5% product gained momentum, with a nearly 45% increase in stack granite volume compared to the prior year [26][32] - The newly launched TNT product exceeded expectations in adoption, indicating strong early demand [11][34] Market Data and Key Metrics Changes - The company ended 2024 with $150 million in cash and marketable securities, with total cash usage in Q4 being less than $800,000 [47] - International revenue for Q4 was $2.1 million, with full-year international revenue at $8.8 million [42] Company Strategy and Development Direction - The company aims to implement targeted commercial initiatives to fuel adoption of its expanded portfolio and grow its physician base [13] - Plans to increase procedure density through multimodality physician engagement and lay groundwork for commercialization of new products [14] - The company is focused on maintaining its leadership position in the market through innovation and strategic partnerships [17][35] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong revenue growth and profitability in 2025, driven by robust procedure demand and a growing physician base [48][51] - The company anticipates worldwide revenue of $193.5 million to $195.5 million in 2025, implying year-over-year growth of approximately 16% to 17% [49] - Management highlighted the importance of clinical publications in accelerating adoption and maintaining differentiated reimbursement [38] Other Important Information - The company is cooperating with the Department of Justice (DoJ) regarding an ongoing investigation, with no material updates expected prior to resolution [39][135] - The company has been awarded breakthrough device designation for a new novel implant system, positioning it as a category creator in the industry [36][100] Q&A Session Summary Question: Growth drivers for the company - Management noted strong momentum across all procedure types, with significant contributions from SI joint fusion, Granite 9.5%, and TNT products [56][58] Question: Guidance for 2025 growth - Management provided a balanced approach to guidance, incorporating assumptions about ASP decline and one less procedure day in the year [62][66] Question: Competitive landscape - Management expressed confidence in maintaining market leadership, supported by a comprehensive product portfolio and strong educational initiatives [71][72] Question: Update on Granite NTAP - Management confirmed that they have submitted an application to CMS for a higher paying code for Granite, with updates expected mid-year [111] Question: Profit ramp cadence through 2025 - Management expects to be adjusted EBITDA positive in the second half of 2025, with a focus on maintaining operating leverage [117][121]

Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 31.25%. A quarter ago, it was expected that this medical device maker would post a loss of $0.22 per share when it actually produced a loss of $0.16, delivering a surprise of 27.27%.Over the last four quarters, the company has sur ...

Achieves 26% worldwide revenue growth and positive adjusted EBITDA in Fourth Quarter 2024SANTA CLARA, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $49.0 million, representing growth of ~26% U.S. revenue of $46.9 m ...

Si-Bone (SIBN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on February 24, 2025, might help the stock move higher if these key numbers are better than e ...

SANTA CLARA, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Monday, February 24, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: ht ...